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The present study explores tissue and cellular distribution of ectonucleoside
triphosphate diphosphohydrolase 2 (NTPDase2) and the gene and protein expression
in rat spinal cord during the course of experimental autoimmune encephalomyelitis
(EAE). Given that NTPDase2 hydrolyzes ATP with a transient accumulation of
ADP, the expression of ADP-sensitive P2 purinoceptors was analyzed as well. The
autoimmune disease was actively induced in Dark Agouti female rats and the changes
were analyzed 10, 15 and 29 days after the induction. These selected time points
correspond to the onset (Eo), peak (Ep) and recovery (Er) from EAE. In control
animals, NTPDase2 was confined in the white matter, in most of the glial fibrillary
acidic protein (GFAP)-immunoreactive (ir) astrocytes and in a considerable number
of nestin-ir cells, while the other cell types were immunonegative. Immunoreactivity
corresponding to NTPDase2 decreased significantly at Eo and Ep and then returned
to the baseline levels at Er. The preservation of the proportion of GFAP single-labeled
and GFAP/NTPDase2 double-labeled elements along the course of EAE indicated
that changes in NTPDase2-ir occurred at fibrous astrocytes that typically express
NTPDase2 in normal conditions. Significant downregulation of P2Y1 and P2Y12 receptor
proteins at Eo and several-fold induction of P2Y12 and P2Y13 receptor proteins at Ep
and/or Er were observed implying that the pathophysiological process in EAE may be
linked to ADP signaling. Cell-surface expression of NTPDase2, NTPDase1/CD39 and
ecto-5′-nucleotidase (eN/CD73) was analyzed in CD4+ T cells of a draining lymph node
by fluorescence-activated cell sorting. The induction of EAE was associated with a
transient decrease in a number of CD4+ NTPDase2+ T cells in a draining lymph node,
whereas the recovery was characterized by an increase in NTPDase2+ cells in both
CD4+ and CD4− cell populations. The opposite was found for NTPDase1/CD39+
and eN/CD73+ cells, which slightly increased in number with progression of
the disease, particularly in CD4− cells, and then decreased in the recovery.
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Finally, CD4+ NTPDase2+ cells were never observed in the spinal cord parenchyma.
Taken together, our results suggest that the process of neuroinflammation in EAE may
be associated with altered ADP signaling.
Keywords: ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2), ADP-sensitive P2 receptors,
experimental autoimmune encephalomyelitis (EAE), CD4+ T cells, neuroinflammation
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune disease
characterized by isolated plaques of demyelination and axonal
loss in the brain and spinal cord (Lassmann et al., 2007;
Lassmann, 2014). Although the exact cause of MS is still
undetermined, the disease is mediated by adaptive immunity
through the infiltration of T cells into the central nervous
system (CNS; for review see, Bjelobaba et al., 2017). Clinical
studies in MS and studies on a widely accepted animal model
of MS, experimental autoimmune encephalomyelitis (EAE),
demonstrate that the autoimmune process is primarily mediated
by self-reactive Th1 and Th17 CD4+ cells which enter the
CNS, where they become reactivated by resident antigen-
presenting microglia, recurrently inducing microglial activation
and consequent demyelination and axonal loss (McFarland and
Martin, 2007).
Besides mononuclear infiltrates and activated microglia,
recent data imply that astrocytes are another key player in
the pathophysiology of MS/EAE (Brück, 2005; Voskuhl et al.,
2009; Lavrnja et al., 2015). In spite of the large heterogeneity,
two main types of astrocytes have been recognized in the
mammalian CNS, based on their morphology and tissue
distribution (for review see, Oberheim et al., 2012); protoplasmic
astrocytes with radially oriented processes are present in
the gray matter in a non-overlapping domain arrangement,
whereas fibrous astrocytes, which extend numerous overlapping
processes along fiber tracts populate the white matter (Oberheim
et al., 2008). Both types of astrocyte support neuronal
stability and contribute to the maintenance of blood–brain
barrier and general homeostasis (for review, see Simard and
Nedergaard, 2004). In neuroinflammatory conditions associated
with MS/EAE, astrocytes acquire activated phenotype and exert
both proinflammatory and neuroprotective actions along the
course of the disease (for review, see Pekny et al., 2016; Bjelobaba
et al., 2017).
Therefore, for MS/EAE to develop, the coordinated action
of several immune and neural cell types is required. One of
the potent triggers of the neuroinflammatory cascade is ATP,
which is released in response to diverse noxious stimuli in
the brain (Melani et al., 2005; Rodrigues et al., 2015). When
present in high concentrations, extracellular ATP acts as a
danger-associated molecular pattern and its signaling through
multiple P2 purinoceptors alarms the immune system (Di
Virgilio et al., 2009; Fiebich et al., 2014). ATP initiates and
coordinates a cross-talk between infiltrated T-cells and resident
microglia and astrocytes (Liu et al., 2011), by recruiting T cells
and facilitating their extravasation into the CNS (Mills et al.,
2012), potentiating the release of cytokines and chemokines
(Bours et al., 2006) and activating and attracting microglia and
astrocytes (Franke et al., 2012), which govern further pathology
in MS (Brück, 2005). Moreover, ATP activates low-affinity
P2X7 receptors and potentiates the release of interleukin-1β
and cyclooxygenase induction (Morán-Jiménez and Matute,
2000), causing demyelination, oligodendrocyte death and axonal
damage (for review, see Matute, 2008).
Extracellular ATP is eliminated by the coordinated action of
ectonucleotidase enzyme cascade. Specifically, ectonucleoside
triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and
ectonucleoside triphosphate diphosphohydrolase 3 (NTPDase3)
hydrolyze ATP to ADP and ultimately to AMP, while
ecto-5′-nucleotidase (eN/CD73) catalyzes the last step of
dephosphorylation, which results in adenosine production
(Zimmermann, 2000; Yegutkin, 2008). The uniqueness of
this enzyme cascade is that each step generates a ligand for
a distinct set of purinergic receptors. Namely, ATP activates
a subset of P2X1-7 receptor channels (Khakh and North,
2012) and G-protein coupled P2Y1−14 receptors (Abbracchio
et al., 2006), while adenosine acts at G-protein coupled
P1 purinoceptors (Bours et al., 2006; Ciruela et al., 2006). Yet
another ectonucleotidase, with specific substrate affinity and
restricted expression in the brain is ectonucleoside triphosphate
diphosphohydrolase-2 (NTPDase2; previously known as
Ecto-ATPase, or CD39L1). In the rodent brain, NTPDase2 is
localized at specialized astrocytes, such as laminar astrocytes
associated with fiber tracts in the brain stem and cerebrum
(Braun et al., 2003, 2004), satellite astrocytes in the dorsal
root ganglion (Braun et al., 2004), tanycytes, non-stellate
astrocytes in the gray matter of discrete regions, like habenula
(Gampe et al., 2012) and astrocyte-like progenitor cells of the
subventricular zone (SVZ) of the lateral ventricle (Shukla et al.,
2005; Mishra et al., 2006; Gampe et al., 2015). The enzyme
preferentially catalyzes the dephosphorylation of ATP to ADP,
generating a ligand for P2Y1, P2Y12 and P2Y13 receptors
(Abbracchio et al., 2006; Burnstock, 2007). There is compelling
evidence for the critical involvement of purinergic signaling in
the control of different aspects of MS/EAE pathophysiology.
A decreased plasma level of adenosine, reduced number of
regulatory CD39+ T cells (Treg) and the reduced expression
of A1 receptor in lymphocytes, together with the dysfunction
of A1, A2A and P2X7 receptors and their altered expression
in the proximity of demyelination lesions in the brain, are
molecular signatures of MS (for review, see Cies´lak et al., 2011;
Burnstock, 2016). Furthermore, pharmacological blockade
of A1 and A2A receptors results in beneficial therapeutic
effects and reduced excitotoxicity and demyelination in
MS (Antonioli et al., 2013; Safarzadeh et al., 2016). Other
studies demonstrated important roles for CD4+CD73+ and
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CD4+CD39+ Th17 cells in the induction (Mills et al., 2008,
2012) and progression of EAE (Hernandez-Mir and McGeachy,
2017). These studies revealed close coupling between purinergic
signaling and the presentation and severity of disease (Lavrnja
et al., 2015). More recent data show that the ADP-sensitive
P2 receptors are involved in the pathophysiology of MS/EAE
(Amadio et al., 2010, 2014; Qin et al., 2017; Zhang et al., 2017).
Specifically, a decrease in P2Y12 receptor protein expression
in the proximity of MS lesions directly correlates with the
extent of demyelination (Amadio et al., 2010) and the severity
of disease (Zhang et al., 2017). Since ADP is generated by
the catalytic action of NTPDase2, we hypothesized that the
enzyme may have a role in neuroinflammatory processes
during MS/EAE, through the modulation of P2Y-mediated
signaling and cell communication. For this reason, we
have analyzed the expression and cellular distribution of
NTPDase2 in the lumbosacral spinal cord of Dark Agouti rats
(DA) during EAE.
MATERIALS AND METHODS
Animals
Eight-week-old female rats of DA strain from the local colony
were used in the study. Littermates were kept in the same
cage (4–5/cage) under constant temperature and humidity, 12 h
light/dark cycle and a free access to laboratory chow and tap
water. Experimental protocols were approved by the Ethical
Committee for the Use of Laboratory Animals of the Institute for
Biological Research ‘‘Sinisa Stankovic’’, University of Belgrade,
Serbia (No. 01-11/14) and were in compliance with the EEC
Directive (2010/63/EU) on the protection of animals used for
experimental and other scientific purposes.
Induction of Experimental Autoimmune
Encephalomyelitis (EAE)
Animals selected for the study were randomly divided into two
groups. In the first group, the animals under ether anesthesia
received a subcutaneous injection of an encephalitogenic
emulsion in the hind footpad. The emulsion was prepared by
mixing equal volumes of rat spinal tissue homogenate (50%
w/v in saline), and complete Freund’s adjuvant (0.5 mg/mL
Mycobacterium tuberculosis; Sigma, St. Louis, MO, USA). All
immunized animals developed signs of acute EAE. A group of
age-matched naïve female rats was used as control group.
Animals were weighed and monitored for the neurological
signs of the disease every day (Figure 1A). During a 30-day
post-induction period (dpi), two unbiased examiners evaluated
the severity of the disease, using standard EAE grading scale
(Milicevic et al., 2003), which converts symptoms to grades,
as follows: unaffected—0; reduced tail tone—0.5; tail atony—1;
slightly/moderately clumsy gait, impaired righting ability or
combination—1.5; hind limb paresis—2; partial hind limb
paralysis—2.5; complete hind limb paralysis—3; complete hind
limb paralysis with forelimb weakness—3.5; tetraplegic—4 and
moribund state or death—5. The daily mean grade was calculated
by averaging daily grades of the animals within the group.
The study included two separate EAE induction and sample
preparation.
The immunization resulted in the acute monophasic disease,
with 100% incidence and recovery. The first signs of EAE
in individual animals appeared at 9 dpi, while at 10 dpi all
animals displayed reduced or lost tail tone. The symptoms
progressively advanced during the next 5 days, with the most
severe presentation of the disease observed between 14 and
15 dpi. After this point, animals began to recover and complete
remission was observed at 24 dpi. Given the monophasic course
of the disease, animals were selected and euthanized at the three
time-points after the immunization, i.e., at 10, 15 or 29 dpi, which
corresponded to the onset (Eo), the peak (Ep) and the recovery
(Er) phase of the disease (Figure 1B).
Spinal Cord Dissection and Tissue
Preparation
The animals were anesthetized and perfused with 0.9% sodium
chloride, positioned in Harvard apparatus and decapitated.
Spinal cords were dissected on ice and their lumbosacral
parts isolated for crude plasma membrane preparation, RNA
extraction and cryosectioning.
Crude Plasma Membrane Preparation
The dissected lumbosacral parts of the spinal cords were pooled
for each group (3/group) and used for crude plasma membrane
preparation by following the protocol of Gray and Whittaker
(1962). Briefly, the tissue was homogenized in the isolation buffer
(0.32 mol/L sucrose, 5 mmol/L Tris, pH 7.4) and centrifuged
at 3000× g for 10 min at 4◦C. Supernatant was separated and
centrifuged again at 12,000× g for 40 min at 4◦C. The resulting
pellets were combined and resuspended in ice-cold 5 mmol/L
Tris pH 7.4. The protein content was determined using Micro
BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL,
USA).
Western Blot
Membrane samples were diluted in 4× Laemmli sample buffer
to a protein concentration of 1 mg/ml and incubated for 5 min at
95◦C. Sample proteins (15µg) were resolved by 7.5% PAGE-SDS
gel under non-reducing conditions, and transferred to a support
membrane (Immobilon-P transfer membrane, Millipore). For
P2Y receptor protein detection, sample proteins were resolved
under reducing conditions. The support membranes were
blocked in 5% BSA or 5% Blotto (Santa Cruz Biotechnology) in
Tris-buffer saline Tween-20 (TBST) and probed with primary
antibodies (as indicated in Table 1), at 4◦C overnight. After
rinsing in TBST (3 × 5 min), the support membranes were
incubated in the appropriate HRP-conjugated IgG secondary
antibodies, for 2 h at room temperature. Bands were visualized
on X-ray films (Kodak, Rochester, NY, USA) with the use
of chemiluminescence (ECL, GE Healthcare). The amount of
sample and titer of the antibodies were chosen to ensure
optimum immunoassay potency (Supplementary Figure S1).
Relative molecular weight of each band on the support
membrane was estimated by the relative migration method and
the bands of interest were chosen based on expected size(s).
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FIGURE 1 | Schematic representation of experimental protocol used for the induction of monophasic experimental autoimmune encephalomyelitis (EAE) in Dark
Agouti (DA) rats. (A) Animals immunized on day 1 (dpi 1) by s.c. injection of the encephalitogenic emulsion developed a disease with 100% incidence. (B) Animals
were weighed and scored daily for neurological signs of EAE using standard 0–5 EAE grading scale. Plots represent the variations in daily mean disease
grade ± SEM (red circles) and mean body mass (blue circles) during EAE, measured in two separate rounds of EAE inductions. The animals were euthanized at 10,
15 and 29 days after immunization, i.e., at the time-points which correspond to the onset of disease (Eo), the peak of neurological symptoms (Ep) and recovery (Er).
(C) Representative micrographs showing the autoimmune-mediated demyelination and axonal degeneration in the spinal cord ventral white matter. Double
immunofluorescence (IF) labeling was performed using antibodies directed against myelin basic protein (MBP; left—green fluorescence) or heavy neurofilament
subunit, NF-H (right—green fluorescence). Nuclei were counterstained with Hoechst (blue fluorescence). Dotted areas show patches of the neurodegeneration.
Scale bar at C = 20 µm.
For NTPDase1/CD39 and eN/CD73, which exist in distinct
molecular weight glycoforms, and P2Y13, which exists in two
protein isoforms, multiple bands based on the expected size
were integrated for a densitometric analysis (ImageJ software
package). The positions of the specific bands are indicated in
Figures 2, 3. The value obtained for a band of interest is
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TABLE 1 | List of antibodies.
Antibody selectivity Source and type Dilution Manufacturer
NTPDase2 (rN2-6L) Rabbit, pc 1:2000 (WB)
1:200 (IHC, IF)
1:100 (FC)
ectonucleotidases-ab.com;Cat# NTPDase2,
RRID:AB_2314986 (Sévigny et al., 2002)
NTPDase1/CD39 (mN1-2C(I4,I5)) Guinea pig, pc 1:6000 (WB)
1:400 (FACS)
ectonucleotidases-ab.com;Cat# NTPDase1
ecto-5′-nucleotidase/CD73 Rabbit, pc 1:5000 (WB) Cell Signaling Technology #3160, RRID:AB_11217629
ecto-5′-nucleotidase/CD73 (rNu-9L(I4,I5)) Rabbit, pc 1:100 (FACS) ectonucleotidases-ab.com;Cat# ecto-5′-nucleotidase/CD73
P2Y1 Rabbit, pc 1:1000 (WB) Alomone Labs; #APR-0009, RRID:AB_2040070
P2Y12 Rabbit, pc 1:1000 (WB) Sigma P4817, RRID:AB_261954
P2Y13 Rabbit, pc 1:1000 (WB) Alomone Labs; #APR-017, RRID:AB_2040076
GFAP Mouse, mc 1:500 (IF) UC Davis/NIH NeuroMab Facility (73–240), RRID:AB_10672298
Nestin Mouse, mc 1:100 (IF) Sigma N5413, RRID:AB_1841032
Iba1 Goat, pc 1:400 (IF) Abcam ab5076, RRID:AB_2224402
ED1/CD68 Mouse, mc 1:100 (IF) Abcam ab31630, RRID:AB_1141557
CD4 Mouse, mc 1:500 (IF)
1:100 (FACS)
Sigma-Aldrich SAB4700733, RRID:AB_476825733
NF-H (SMI32) Mouse, mc 1:2000 (IF) Covance Research Products Inc AB_509997, RRID:AB_509997
MBP Mouse, mc 1:100 (IF) BioLegend 801703, RRID:AB_510039
NG2 Mouse, mc 1:50 (IF) Sigma N8912, RRID:AB_609907
Oligodendrocyte marker O4 Mouse, mc 1:100 (IF) Millipore MAB345, RRID:AB_11213138
β-Actin Mouse, mc 1:7500 (WB) Sigma A5316, RRID:AB_476743
Anti-rabbit HRP conjugated IgG Donkey, pc 1:5000 (IHC) Santa Cruz, sc2305, RRID:AB_641180
Anti-rabbit IgG AlexaFluor 555 Donkey, pc 1:200 (IF) Invitrogen A-21428, RRID:AB_141784
Anti-mouse IgG AlexaFluor 488 Donkey, pc 1:200 (IF, FACS) Invitrogen A21202, RRID:AB_141607
Anti-mouse HRP conjugated IgG Donkey, pc 1:5000 (WB) Santa Cruz sc-2314, RRID:AB_641170
Anti-goat IgG Alexa Fluor 488 Donkey, pc 1:250 (IF) Invitrogen A-11055, RRID:AB_142672
Anti-rabbit IgG AlexaFluor 488 Donkey, pc 1:200 (IF) Invitrogen A-21206, RRID:AB_141708
Anti-mouse IgG AlexaFluor 555 Donkey, pc 1:200 (IF, FACS) ThermoFisher Scientific A-31570, RRID:AB_2536180
WB, Western blot; IFC, Immunohostochemistry; IF, immunofluorescence; FC, flow cytometry; mc, monoclonal; pc, polyclonal.
normalized to the optical density (OD) of β-actin band on the
same lane and presented relative to control (100%) ± SEM. The
bars represent means from n ≥ 3 separate determinations. A list
of primary and secondary antibodies is given in Table 1.
Immunohistochemistry for Light
Microscopy and Immunofluorescence
Cross-cryosections of the lumbosacral spinal cord were used
for immunohistochemical staining. For light microscopy, the
sections were incubated in 1% hydrogen peroxide (in methanol)
followed by incubation in 10% normal donkey serum, to block
endogenous peroxidase and prevent non-specific labeling. The
sections were probed with anti-NTPDase2 primary antibodies,
overnight at 4◦C, rinsed in PBS and incubated with secondary
HRP-conjugated donkey anti-rabbit antibodies, for 2 h, at
room temperature. The identity of the antibodies and dilutions
used for immunohistochemistry are indicated in Table 1.
The signal was visualized using 3,3′-S-diaminobenzidine-
tetrahydrochloride (DAB, Dako, Glostrup, Denmark) as a
substrate. Incubation without primary antibodies resulted in the
absence of any specific reaction. After dehydration, sections
were mounted using DPX Mounting medium (Fluka, Buchs,
Switzerland), and examined under a Zeiss Axiovert microscope
(Carl Zeiss GmbH, Vienna, Austria).
For double immunofluorescence (IF) labeling, 20-µm thick
cryosections blocked with 1% BSA (Thermo Fisher Scientific,
Rockford, IL, USA) were incubated with anti-NTPDase2
antibodies, overnight at 4◦C. After thorough rinsing in PBS,
secondary donkey anti-rabbit IgG Alexa Fluor 555 antibodies
were applied. For second labeling, primary antibodies directed
against glial fibrillary acidic protein (GFAP), ionizing calcium-
binding adaptor molecule 1 (Iba1), CD68, nestin, neurofilament
heavy polypeptide (NF-H), myelin basic protein (MBP) and
oligodendrocyte marker 4 (O4), (overnight at 4◦C) and
secondary IgG AlexaFluor 488 antibodies were applied. Nuclei
were counterstained by Hoechst 33342 dye (5 µg/ml—Life
Technologies, Invitrogen, Carlsbad, CA, USA). Sections were
mounted in Mowiol (Calbiochem, Millipore, Germany) and
captured by a camera associated with Zeiss Axiovert fluorescent
microscope (Zeiss, Jena, Germany).
Quantification
The spinal cord sections from the lumbosacral segments, labeled
for NTPDase2/GFAP or NTPDase2/nestin, were used for the
quantification. Each section was arbitrarily divided into four
quadrants, on the basis of the dorsal/ventral and right/left
symmetry. Two to four microscopic fields per each quadrant
were captured and stored as digital data. Digital images were
examined and each quadrant was independently counted for
single-labeled (NTPDase2, GFAP, nestin) and double-labeled
(NTPDase2/GFAP and NTPDase2/nestin) cellular processes.
In all cases, labeling in the respective single channels was
directly compared with the superimposed images. Representative
single-channel images of sections labeled for NTPDase2 and
individual cell markers are presented in Supplementary
Figures S2–S4. The results are expressed as mean % of
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FIGURE 2 | Expression analysis of ectonucleotidases during EAE. Transcriptional expression of ectonucleoside triphosphate diphosphohydrolase 2 (NTPDase2) (A),
NTPDase1/CD39 (D) and ecto-5′-nucleotidase (eN/CD73) (G). Bars represent mean target/GAPDH-mRNA abundance (± SEM), determined in total RNA isolated
from the lumbar spinal cord of control rats (100%) and rats at Eo, Ep and Er. Dot line represents mean target/GAPDH-mRNA abundance (± SEM, gray area)
determined in control animals. Samples are from three animals per group. ∗p < 0.01; ∗∗p < 0.001 (analysis of variance, ANOVA followed by Tukey’s post hoc test).
Relative protein abundance of NTPDase2 (B), NTPDase1/CD39 (E) and eN/CD73 (H) in crude plasma membrane preparations obtained from control animals and at
each phase of EAE. The intensity of each protein band of interest was assessed by densitometric measurements using ImageJ software and expressed relative to
the optical density (OD) of the β-actin band in the same lane (target protein/β-actin ratio). The target protein/β-actin value obtained for the control sample was defined
as 100% (dot line) ± SEM (gray area) and the ratios obtained for other samples were expressed relative to the control (bars). Bars represent the mean target protein
abundance (± SEM) from n ≥ 4 determinations performed on at least two independent sample preparations. Significance inside the graph: ∗p < 0.01; ∗∗p < 0.001.
Representative support membranes showing the position of bands corresponding to NTPDase2 (C), NTPDase1/CD39 (F) and eN/CD73 (I), visualized on X-Ray
films with the use of chemiluminescence.
single-labeled or double-labeled elements relative to the total
number of labeled elements (±SEM), from six cross-sections
of the spinal cord per animal (three animals per each EAE
group).
Quantitative Real-time PCR
Lumbosacral parts of the spinal cords (5/group) were frozen
in liquid nitrogen and kept at −80◦C until use. RNA
extraction was performed using TRIzolr reagent, according to
the manufacturer’s instructions. RNA content was measured
spectrophotometrically by determining OD at 260 nm, while the
purity of the samples was assessed by determining OD260/OD280
and OD260/OD230 ratios. A volume equivalent to 1 µg of RNA
was used for reverse transcription with High Capacity cDNA
Reverse transcription kit (Applied Biosystems, Foster City, CA,
USA). The obtained cDNA samples were used for real-time
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FIGURE 3 | Expression analysis of ADP-sensitive purinoceptors during EAE. Transcriptional expression of P2Y1 (A), P2Y12 (D) and P2Y13 (G). Bars represent mean
target/GAPDH-mRNA abundance (± SEM), determined in total RNA isolated from lumbar spinal cords of control rats (100%) and rats at Eo, Ep and Er. Dot line
represents mean target/GAPDH-mRNA abundance ± SEM (gray area) determined in control animals. Samples are from three animals per each group. ∗p < 0.01
(ANOVA followed by Tukey’s post hoc test). Relative protein abundance of P2Y1 (B), P2Y12 (E) and P2Y13 (H) in crude plasma membrane preparations obtained from
control and EAE animals. The intensity of each specific band was assessed by densitometric measurements using ImageJ software and expressed relative to the OD
of the β-actin band in the same lane (target band/β-actin ratio). The ratio obtained from control crude plasma membrane preparation was defined as 100% (dot
line) ± SEM (gray area) and the ratios obtained for other samples were expressed relative to control (bars). Bars represent mean target-protein abundance (± SEM)
from n ≥ 3 determinations performed on at least two independent sample preparation. Significance inside the graph: ∗p < 0.05, ∗∗p < 0.001. Representative support
membranes showing the position of bands corresponding to P2Y1 (C), P2Y12 (F) and P2Y13 (I), visualized on X-Ray films with the use of chemiluminescence.
PCR analysis with the QuantStudioTM 3 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Reactions were
carried out in amixture consisting of 2µl cDNA, 2µl RNase-free
water (UltraPure, Invitrogen, Germany), 5 µl QTM SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA,
USA) and 0.5 µl primers (100 pmol/µl), under the following
conditions: 10 min of enzyme activation at 95◦C, 40 cycles of 15 s
denaturation at 95◦C, 30 s annealing at 64◦C, 30 s amplification
at 72◦C and 5 s fluorescence measurement at 72◦C. Primer
sequences are listed in Table 2. Relative abundance of specific
mRNA was determined by the 2−∆Ct method, using GAPDH
as the internal standard. The results are expressed as target-
mRNA/GAPDH-mRNA ratio (relative to the ratio obtained for
control).
Flow Cytometry
Popliteal lymph nodes were removed, homogenized through
a nylon sieve and centrifuged at 700× g for 3 min.
Pellets were resuspended in PBS and filtered through sterile
50 µm filters. Cells were counted and 106 cells were
centrifuged and resuspended in PBS with 10% normal rat
serum with primary antibodies directed to CD4 and NTPDase2,
NTPDase1/CD39 and eN/CD73 (Table 1), for 45 min at
4◦C. Cells were washed twice with PBS and incubated with
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TABLE 2 | Primer sequences.
Target Forward Reverse
gene
Nt5e CAAATCTGCCTCTGGAAAGC ACCTTCCAGAAGGACCCTGT
Entpd1 TCAAGGACCCGTGCTTTTAC TCTGGTGGCACTGTTCGTAG
Entpd2 CCCTCATGACCTTCTTCCTG CCAAGAGACCCGGTATAGCA
P2ry1 CTGGATCTTCGGGGATGTTA CTGCCCAGAGACTTGAGAGG
P2ry12 CGAAACCAAGTCACTGAGAGA CCAGGAATGGAGGTGGTGTTG
P2ry13 GGCATCAACCGTGAAGAAAT TTGGCAATCACCGTGTAAAA
P2rx1 GTGTTTGGGATTCACTTTGATA TCTGCTTGTAGTAGTGCCTCTT
P2rx2 AGAAGAGTGACTACCTCAAGCA ACAGTTCCAGTTGATGATGACT
P2rx3 CCTCACCGACAAGGACATA ACACCCAGCCGATCTTAAT
P2rx4 TCCTGATAAGACCAGCATTT CAAGAGGGTGAAGTTTTCTG
P2rx5 CAAATCTCTACTGTCCCATCTT TAGTAGTGTGGGTTGCATTTAG
P2rx7 TCGGAGAGAACTTTACAGAGG TCGGAGAGAACTTTACAGAGG
Adora1 GTGATTTGGGCTGTGAAGGT GAGCTCTGGGTGAGGATGAG
Adora2a TGCAGAACGTCACCAACTTC CAAAACAGGCGAAGAAGAGG
Adora2b CGTCCCGCTCAGGTATAAAG CCAGGAAAGGAGTCAGTCCA
Adora3 TTCTTGTTTGCCTTGTGCTG AGGGTTCATCATGGAGTTCG
Gapdh TGGACCTCATGGCCTACAT GGATGGAATTGTGAGGGAGA
the appropriate secondary antibodies (listed in Table 1).
After thorough washing in PBS, flow cytometric analysis was
performed in CyFlowr Space Partec (Partec GmbH, Munster,
Germany). Data were analyzed using PartecFloMaxr (Partec
GmbH, Munster, Germany) software.
Data Analysis
Statistical analyses were performed in OriginPro8 SR0 software
package (v8.0724, OriginLab Corporation, Northampton, MA,
USA), using one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test. The data are presented as mean± SEM and
considered statistically significant at p< 0.05.
RESULTS
Disease Symptoms and Histopathological
Changes during EAE
The experimental design of the study is shown in Figure 1A.
Active immunization led to a monophasic disease with 100%
incidence and recovery. Daily mean disease grade and body
mass variations during a 30-day period after induction (dpi) are
presented in Figure 1B. A maximum daily mean grade and a
peak of body weight reduction were demonstrated at 15 dpi,
which was defined as the peak of disease (Ep). To confirm
that the neurological deficits in EAE animals were caused by
autoimmune-mediated demyelination and axonal degeneration,
IF labeling directed to MBP and heavy neurofilament subunit
(NF-H) was performed (Figure 1C). Immunolabeling for MBP
andNF-H revealed large areas of neurodegeneration in the spinal
white matter at Ep.
Expression of NTPDase2 and
ADP-Sensitive P2 Purinoceptors Change
Over the Course of the Disease
The expression of NTPDase2 was analyzed in the lumbosacral
part of the spinal cords during EAE. A strong down-regulation
of NTPDase2 gene and protein expression at Eo and Ep and
the baseline expression at Er were observed (Figure 2). At
the peak of disease, the abundance of NTPDase2, at mRNA
(Figure 2A) and protein (Figures 2B,C) levels decreased to
about 30% (p < 0.001) and 40% (p < 0.001) of those detected
in naïve animals, respectively. Since purine nucleotides are
dephosphorylated in a stepwise manner by a coordinated
action of ectonucleotidases, gene and protein expression
profiles of two major ectonucleotidases, NTPDase1/CD39 and
eN/CD73 were determined as well (Figure 3). A strong
induction of NTPDase1/CD39 (Figures 2D–F) and eN/CD73
(Figures 2G–I) was demonstrated at mRNA (Figures 2D,G) and
protein levels (Figures 2E,H) at Ep and Er.
Together, the results obtained imply a general shift in the
availability of ligands for P1 and P2 receptors during EAE.
To estimate the physiological significance of the observed
alterations and to gain a better insight into the circumstances
in which they occurred, we analyzed the expression profiles of
ADP-sensitive P2Y1, P2Y12 and P2Y13 receptors. The expression
of P2Y1 (Figures 3A–C) and P2Y12 receptors (Figures 3D–F)
consistently decreased at mRNA and protein levels at Eo,
whereas at Ep and/or Er, P2Y12 (Figures 3D–F) and P2Y13
(Figures 3G–I) receptor gene and protein expression increased
several-fold. We further screened the abundance of mRNA
coding for ATP-sensitive P2X and adenosine P1 receptors
during EAE, in order to evaluate the possible consequences on
ATP- and adenosine-mediated signaling. A consistent decrease
in the abundance of transcripts coding for P2X1, P2X2, P2X3,
P2X4, P2X5 and P2X7 purinoceptors, particularly during the
symptomatic stages of the disease, indicated the attenuation in
P2X-mediated ATP signaling, while a significant decrease in
A1- and A2B-, and an up-regulation of A2A- and A3-mRNA
levels, were observed (Table 3).
Tissue localization of NTPDase2 in the spinal cord
was demonstrated by immunohistochemistry, using
the well-characterized rN2-6L antibodies directed to
NTPDase2 (Figure 4). In control sections, strong
NTPDase2 immunoreactivity (ir) was confined mainly to
fibrous elements in the white matter (Figure 4B), whereas
labeling in the gray matter was weak and indistinct (Figure 4C).
Light microscopic examination implied that the NTPDase2-ir
elements in the white matter corresponded to fibrous astrocytes
processes. In sections obtained at Eo and Ep the overall intensity
TABLE 3 | Expression profiles for selected P2X and P1 receptor genes.
Target gene/GAPDH-mRNA (% of control)
Target gene Eo Ep Er
P2X1 40.1 ± 17.5∗ 78.5 ± 22.6 78.1 ± 32.9
P2X2 66.8 ± 1.7 32.5 ± 0.5∗ 96.8 ± 21.1
P2X3 31.3 ± 7.1∗ 11.8 ± 0.6∗ 74.6 ± 16.0
P2X4 36.5 ± 26.9∗ 105.4 ± 9.8 161.0 ± 17.273
P2X5 75.1 ± 19.0 22.5 ± 15.1∗ 99.5 ± 26.1
P2X7 69.7 ± 14.6∗ 72.4 ± 11.6 182.9 ± 36.2
A1 65.6 ± 9.7∗ 40.3 ± 4.2∗ 98.9 ± 14.2
A2A 197.6 ± 93.7 125.0 ± 3.0 138.0 ± 15.3
A2B 55.1 ± 11.8∗ 68.5 ± 27.0∗ 134.3 ± 45.73
A3 366.4 ± 40.0∗ 329.5 ± 11.5∗ 299.2 ± 8.1∗
Statistical significance: ∗p < 0.05.
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FIGURE 4 | Immunohistochemical localization of NTPDase2 in the
lumbosacral spinal cord. Low-power magnification micrographs showing the
distribution of NTPDase2-ir elements in control spinal cord cross-sections
(A) and during the course of the disease (D,G,J). High-power micrographs of
the areas enclosed by rectangles denoted with the same letter, show
NTPDase2-ir in spinal cord white (B,E,H,K) and gray matter (C,F,I,L) in
control sections and over the course of EAE. Scale bar at (J) applicable to
A,D,G = 200 µm; Scale bar at (L), applicable to B,C,E,F,H,I,K = 20 µm.
of NTPDase2-ir decreased (Figures 4E,H), while at Er, the
intensity of NTPDase2-ir was comparable to the intensity
observed in control sections (Figure 4K).
NTPDase2 Immunofluorescence
The precise cellular localization of NTPDase2 in the spinal
cord was further determined by double IF labeling with
antibodies directed to known cellular markers. Astrocytic
localization of NTPDase2 was assessed by double IF labeling of
NTPDase2 and GFAP (Figure 5, Supplementary Figure S2).
In sections obtained from naïve animals, NTPDase2-
ir was detected in the white matter only, in association
with most of the GFAP-ir fibrous astrocytes (Figure 5A).
During the course of EAE, the overall intensity of GFAP-
ir progressively increased at hypertrophied astrocytes
throughout the spinal cord parenchyma, while the intensity
of NTPDase2-ir visibly decreased in the white matter
(Figures 5C,E,G). However, the number of GFAP single-labeled
and GFAP/NTPDase2 double-labeled processes determined
at each phase of EAE revealed that, although the intensity of
NTPDase2-ir varied during EAE, the number of double-labeled
GFAP/NTPDase2 elements remained the same during the whole
course of the disease, indicating that the observed changes
in the NTPDase2 expression occurred in the same subset
of cells.
In inflammatory conditions, astrocytes undergo significant
morphological and functional changes and express many
different molecules, including intermediate filament protein
nestin, a marker of neural stem and progenitor cells.
Therefore, we next tested whether the NTPDase2 labeled
astrocytes displayed heterogeneity regarding the expression
of nestin (Figures 5I–P, Supplementary Figure S3). In
control conditions, nestin-ir was detected in fibrous elements
(Figures 5I,J) and partially overlapped with GFAP-ir (data
not shown). Among the immunolabeled processes in the
white matter, about 75% and 5% were either NTPDase2- or
nestin single-labeled elements, while the remaining 20% were
double-labeled for NTPDase2 and nestin (Figure 5I). During the
course of EAE, overall nestin-ir increased (Figures 5K–N). In
the gray matter, nestin-ir was observed in oval (Figures 5L,N)
and fusiform cells (Figure 5P) with multiple radial processes,
which were never NTPDase2-ir. In the white matter, both
the overall intensity and the number of nestin-ir processes
increased (Figures 5K,M), resulting in about 40% of nestin
single-labeled and about 30% of NTPDase2/nestin double-
labeled elements at Ep (Figure 5R). In the final phase of EAE,
only about 15% of the fibrous elements in the white matter
were NTPDase2 single-labeled elements, while the others were
either NTPDase2/nestin double-labeled or nestin single-labeled
(Figure 5R).
The expression of NTPDase2 was also studied in microglial
cells, which were strongly activated during EAE (Figure 6,
Supplementary Figure S4). The association was assessed by
double IF labeling using anti-Iba1 and anti-CD68 antibodies,
which tag different functional states of microglial cells. Although
NTPDase2-ir was never observed in either quiescent or activated
microglia, the latter cells exhibited a spatial association with
NTPDase2-ir elements during EAE. Namely, at Ep, a number of
ovoid Iba1-ir cells and CD68+ cells were seen (Figures 6E,M),
often in the proximity or surrounded by NTPDase2-ir elements
(Figures 6E–N).
No co-localization was observed between NTPDase2 and
cellular markers for premyelinating oligodendrocytes (O4),
oligodendrocyte progenitor cells (NG2), mature myelin (MBP)
and neurons (NF-H subunit), as determined by double IF (data
not shown).
Expression of NTPDase2 at CD4+ T Cells
Given the fact that EAE is mediated by self-reactive CD4+
T cells entering the spinal cord parenchyma, we explored
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FIGURE 5 | Characterization of NTPDase2-ir spinal cord cross-sections during EAE by using double IF labeling. (A–H) Representative micrographs showing
colocalization of NTPDase2-ir (red fluorescence) and glial fibrillary acidic protein (GFAP)-ir (green fluorescence) in spinal white (wm) and gray (gm) matter, in a control
section and during EAE. (Q) Quantification of GFAP single-labeled and GFAP/NTPDase2 double-labeled processes. Bars represent mean % of GFAP single-labeled
(green bars) and GFAP/NTPDase2 double-labeled (orange bars) fibrous elements, relative to the total number of labeled processes (± SEM), counted from at least
six sections, from three different animals per EAE phase. (I–P) Representative micrographs showing localization of NTPDase2 single-labeled (red fluorescence),
nestin single-labeled (green fluorescence) and NTPDase2/nestin double-labeled elements (orange) in control sections and over the course of EAE. Nuclei are
counterstained with Hoechst (blue fluorescence). The scale bar at (P) applicable to all micrographs = 20 µm. (R) Quantification of NTPDase2 single-labeled (red
bars), nestin single-labeled (green bars) and NTPDase2/nestin double-labeled (orange bars) fibrous elements. Results present mean % of each label relative to a total
number of labeled processes (± SEM), counted from at least six sections, from three different animals per each EAE phase. Significance inside of graph: ∗p < 0.05,
∗∗p < 0.001.
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FIGURE 6 | Association of NTPDase2 with markers of microglia. (A–H) Representative micrographs showing double IF labeling directed to NTPDase2 (red
fluorescence) and Iba-1 (green fluorescence) at spinal cord sections in control and during EAE. (I–P) Representative micrographs showing double fluorescence
labeling directed to NTPDase2 (red fluorescence) and CD68 (green fluorescence). Nuclei are counterstained with Hoechst (blue fluorescence). The scale bar at (P)
applicable to all micrographs = 20 µm.
the surface expression of NTPDase2 at CD4+ cells, both at
spinal cord infiltrates (Figure 7) and in a draining lymph
node (DLN, Figure 8). The cells infiltrated in the spinal
cord parenchyma were first seen at Ep, as clusters of CD4+
and CD4− cells, ranging from few to several dozens per
×40 field (Figures 7E,F). These CD4+ T cells were never
observed to express NTPDase2. On closer examination, the
infiltrates were often seen in juxtaposition with NTPDase2-ir
fibrous elements, which appeared to surround or wall off the
clusters of the inflammatory cells (Figure 7E). At Er, numerous
infiltrates were still seen, particularly in the dorsal white matter
(Figure 7G).
The contribution of NTPDase2+ cells to total cell population
in DLN was analyzed by fluorescence-activated cell sorting,
after staining the cells with fluorescence-labeled antibodies
directed against CD4 and NTPDase2 (Figures 8A,B). In
parallel, we analyzed the contributions of NTPDase1/CD39+
(Figures 8C,D) and eN/CD73+ cells (Figures 8E,F) in the
same lymph node. In control animals, CD4+ T cells comprised
∼62% of total DLN cell population and contributions of
NTPDase2+, NTPDase1/CD39+, and eN/CD73+ cells are
presented in Table 4. Among CD4+ T cells, more than
50% were NTPDase2+ (Figure 8A), and about 40% were
eN/CD73+ (Figure 8E), while only 10% were NTPDase1/CD39+
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FIGURE 7 | Association of NTPDase2 with CD4+ infiltrates in EAE.
(A–H) Representative micrographs showing cellular infiltrates comprising
CD4+ and CD4− cells over the course of EAE. CD4+ cells (green
fluorescence), which appear at Ep, were usually surrounded by NTPDase-ir
elements, whereas colocalization of NTPDase2 at CD4+ was never observed.
Nuclei were counterstained with Hoechst (blue fluorescence). Scale bar at (H)
applicable to all micrographs = 20 µm.
(Figure 8B). In contrast, the contribution of NTPDase2+
cells to CD4− cell population in control animals was much
lower (Figure 8B). The onset of disease was associated with
a transient decrease in the number of CD4+ NTPDase2+
cells (Figure 8A) and notable increase in NTPDase1/CD39+
(Figure 8D) and eN/CD73 cells (Figure 8F) within CD4−
cells. At Ep, a general increase in NTDPase1/CD39+ cells
(Figures 8C,D) and an increase in eN/CD73+ cells within
the CD4− cell population (Figure 8F) were observed. At Er,
the contribution of NTPDase2+ cells increased in both CD4+
(Figure 8A) and CD4− cells (Figure 8B), the contribution of
eN/CD73+ cells in CD4+ T cells decreased (Figure 8E), while
distribution of NTPDase1/CD39 cells returned to the baseline
(Figures 8C,D).
DISCUSSION
The growing body of literature supports the view that
extracellular purine nucleotides and nucleosides play important
roles in neuron-to-glia and glia-to-glia communications, both
in health and disease (Fields and Burnstock, 2006; Franke
et al., 2012; Burnstock, 2016). Compelling evidence support
the critical role of P2X7-, A1- and A2A-mediated signaling
in the pathophysiology of EAE (for review, see Cies´lak
et al., 2011; Safarzadeh et al., 2016), while the involvement
of ADP-sensitive P2Y12 receptor is recently implicated as
well (Qin et al., 2017; Zhang et al., 2017). The goal of
the present study was to complement existing knowledge
by studying the expression of NTPDase2 and ADP-sensitive
P2 receptors in the spinal cord over the course of EAE since
their contribution to the pathophysiological process is largely
unknown.
Our study confirms that NTPDase2 exhibits a selective
localization in the CNS (Braun et al., 2004; Shukla et al., 2005;
Mishra et al., 2006; Gampe et al., 2015), in contrast to general
expression by astrocytes in vitro, where it represents the major
ectonucleotidase (Wink et al., 2006; Brisevac et al., 2015). In the
rat spinal cord, NTPDase2 is restricted to the white matter, where
it resides in most of the GFAP-ir fibrous astrocytes, while typical
protoplasmic astrocytes, neurons, microglia, oligodendrocytes
and NG2+ cells are essentially devoid of NTPDase2. The
NTPDase2-containing fibrous astrocytes are elongated and
similar in appearance to laminar astrocytes which form sheets
aroundmyelinated fiber bundles (Braun et al., 2003; Shukla et al.,
2005; Gampe et al., 2012). Among these NTPDase2-ir elements
in the spinal cord, roughly 20% co-express neural stem cell
marker nestin, indicating that they may belong to neural stem
cells (Shukla et al., 2005; Mishra et al., 2006; Gampe et al., 2015),
scattered in the spinal white matter (Wei et al., 2002). Therefore,
NTPDase2 is present in the rat spinal cord, in a population of
GFAP-ir fibrous astrocytes, some of which may belong to adult
progenitor cells.
The present study discloses a novel finding that the protein
levels of NTPDase2 in the spinal cord alter during EAE in a
disease-phase specific manner, wherein the decrease in the
membrane expression directly correlates with a severity of
symptoms. Namely, during the symptomatic phases of EAE, the
mRNA and protein expression of NTPDase2 progressively
decrease, while the recovery in NTPDase2 gene and
protein expression accompanies the recovery from the
disease. Counting the number of GFAP single-labeled and
GFAP/NTPDase2 double-labeled elements at each phase of
the disease revealed that the intensity of NTPDase-ir, but
not the number of NTPDase2–ir elements, change during
EAE, indicating that alterations in NTPDase2 expression
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FIGURE 8 | Contribution of NTPDase2+, NTPDase1/CD39+ and eN/CD73+ cells to total cells in draining lymph node during EAE. Contribution of NTPDase2+ cells
to CD4+ (A) and CD4− (B) cell populations. Contribution of NTPDase1/CD39+ cells to CD4+ (C) and CD4− (D) cell populations. Contribution of eN/CD73+ cells to
CD4+ (E) and CD4− (F) cell populations. Dot lines at each graph represent mean contribution (%) ± SEM (gray area) of the target of interest in total T cell population
in DLN, determined in control animals. Bars represent mean contribution (% ± SEM) of cells expressing target antigen in total T cell population in DLN, as determined
from two separate lymphocyte isolations and fluorescence-activated cell sorting. Significance inside the graph: ∗p < 0.05; ∗∗p < 0.001.
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TABLE 4 | Contribution of CD4+, NTPDase2+, NTPDase1/CD39+ and
eN/CD73+ cells to total population of cells in draining lymph node during EAE.
Control Eo Ep Er
(% of total cell population)
CD4+ 62.2 ± 1.3 52.1 ± 0.8∗ 58.8 ± 1.2 53.9 ± 0.8∗
NTPDase2+ 50.7 ± 3.0 38.6 ± 2.9∗ 54.0 ± 3.2 64.3 ± 5.2
CD39+ 23.3 ± 1.2 39.8 ± 1.4∗ 44.4 ± 1.4∗ 30.7 ± 0.6∗
CD73+ 53.0 ± 7.45 62.1 ± 0.9 68.0 ± 4.3 50.2 ± 2.9
Statistical significance: ∗p < 0.05.
occur in the same cell subset, i.e., at fibrous astrocytes which
typically express NTPDase2 in the normal spinal cord. On
the other hand, the contribution of NTPDase2/nestin double-
labeled elements increases toward the end of the disease,
indicating that the recovery from EAE is associated with
the increase in number of progenitor cells in the spinal
cord.
While the overall expression of NTPDase2 markedly
decreases in lumbosacral part of the spinal cord, the gene and
protein expression of NTPDase1/CD39 and eN/CD73 markedly
increase at Ep in comparison to control (Lavrnja et al., 2009,
2015). Of note is that under acute inflammatory conditions
in vitro, cultured astrocytes also respond by reducing the
expression of NTPDase2 (Brisevac et al., 2015). Although only
direct in vivo measurements of the extracellular nucleotide
concentrations would be evidence for a change in the
extracellular purine metabolism, the alterations in the expression
of the whole enzyme chain for extracellular ATP hydrolysis imply
that there are corresponding alterations in the ectonucleotidase
activities during EAE. Indeed, a significant increase in ATP,
ADP and AMP hydrolyzes has already been demonstrated
in the spinal cord tissue during the symptomatic phase of
EAE (Lavrnja et al., 2009, 2015), with the kinetic parameters
which indicate an increase in CD39/NTPDase1 and reduction
in NTPDase2 hydrolyzing activities (Lavrnja et al., 2009).
The aforementioned shifts in the expression and activity of
ectonucleotidases presumably result in the lower availabilities
of ATP and ADP as ligands for the respective P2 receptors. We,
indeed, found significantly altered expression of ADP-sensitive
P2 receptors, i.e., down-regulation of P2Y1 and P2Y12 receptor
proteins at the onset of EAE, and several-fold increase in the
expression of P2Y12 and P2Y13 receptor proteins at Ep and/or
Er. The results of gene expression analyses also demonstrated
consistent down-regulation of P2X purinoceptors genes (this
study; Lavrnja et al., 2015) and a shift in the expression
of P1 receptor genes, i.e., downregulation of A1 and A2B,
moderate increase in A2A and several-fold induction in A3
receptor genes. Although based on transcriptional analyses,
our results corroborate essential and complex role(s) of
ATP- and adenosine-mediated signaling in the pathogenesis of
MS/EAE (for review, see Cies´lak et al., 2011; Safarzadeh et al.,
2016).
What (patho)physiological implications emerge from these
data? Disease-phase specific alterations in NTPDase2 protein
expression suggest that there are corresponding alterations
in the enzyme activity and the availability of ADP in the
extracellular milieu during EAE. These data, together with the
altered expression of ADP-sensitive P2 receptors suggest that
pathophysiological processes in EAE may be associated with
the differential activity of ADP signaling. Among three of the
dominant ADP-sensitive P2Y receptors, only P2Y12 receptor
have been implicated so far in the pathophysiology of MS/EAE.
The study of Amadio et al. (2010) reported that the expression of
P2Y12 receptor protein in the vicinity of demyelinating lesions
inversely correlated with the extent of demyelination in MS.
The P2Y12 receptor exhibits specific cellular localization, being
expressed by oligodendrocytes (Sasaki et al., 2003; Amadio et al.,
2010) and quiescent microglia (Sasaki et al., 2003), while its
down-regulation in ramified microglia reflects the cell transition
from quiescent to the activated phenotype. In this respect,
the established localization of NTPDase2 at fibrous astrocytes
which are wrapping myelinated fibers and its absence from
protoplasmic astrocytes, neurons, and microglia may suggest
a role of NTPDase2 in ADP-mediated signaling between the
axon/oligodendrocyte unit on one side and surveillant microglia
on the other. Specifically, in normal conditions, the electrical
activity of axons causes the tonic release of ATP, which,
after being converted to ADP, activates the P2Y12 receptor
and sustains quiescent microglial phenotype. Pathological
or homeostatic imbalance may induce down-regulation of
NTPDase2 and consequent decrease in ADP-dependent P2Y12
receptor activation at oligodendrocyte/microglia interface. This
may act as an alarm signal to promote the transition of
quiescent microglia to M2/M1 phenotype and the induction
of neuroinflammation. A lack of P2Y12 receptor activation
may also promote direct or indirect effects on oligodendrocyte
survival and axonal loss (Amadio et al., 2010). In addition,
a recent article describes the critical role of P2Y12 receptor
in Th17 differentiation and pathogenesis of EAE (Qin et al.,
2017).
Another novel finding presented herein is the significant
up-regulation of P2Y13 receptor at Er, indicating that the
induction of this P2 purinoceptor may be associated with the
resolution of neuroinflammation and a recovery from the
disease. The suggestions are corroborated by findings that
the activation of P2Y13 receptor induces main pro-survival
pathways in neurons, such as ERK1/2 and PI3K/Akt/GSK3
(Pérez-Sen et al., 2015), which are normally activated by
trophic factors, and the activation of the Nrf2/HO-1 axis
which protects from excitotoxic damage (Espada et al.,
2010). These findings link ADP to neuroprotection and
imply that, in contrast to ATP, ADP may promote survival
and increased neuronal resistance to different insults
(del Puerto et al., 2012). In this sense, activation of the
P2Y13 receptor may have a pivotal role in challenging
conditions during neuroinflammation and therefore, may
provide a potential target for the neuroprotective action in
MS/EAE.
Given the role of CD4+ T cells in the pathophysiology
of EAE/MS (McFarland and Martin, 2007) and the fact
that these cells significantly contribute to mononuclear tissue
infiltrates, the second goal of the present study was to explore
the association of NTPDase2 with CD4+ cells at distinct
phases of EAE. To our knowledge, this is the first report
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on the occurrence and abundance of CD4+NTPDase2+ T
cells, their infiltration into the spinal cord and temporal
changes in EAE. Since our study did not differentiate between
subsets of CD4+ T cells, i.e., Th1, Th2, Th17, Tfh and
Treg (Nakayamada et al., 2012), the findings obtained in
our study may support only three broad conclusions: (a) the
presence of NTPDase2 does not distinguish between the two
main T cell subsets, as both CD4+ and CD4− cells in DLN
expressed NTPDase2. However, it is of note that in physiological
conditions, a considerable number of CD4+ cells expressed
NTPDase2. (b) The onset of EAE coincided with a reduction in
CD4+NTPDase2+ cell number at DLN, whereas the resolution
went together with the elevation of both CD4+NTPDase2+ and
CD4−NTPDase2+ cell numbers. The opposite was found for
cells expressing NTPDase1/CD39 and eN/CD73, which were
slightly increased in number at the onset of EAE and returned
to baseline level at the recovery. (c) Spinal cord infiltrates,
comprising a mixed population of CD4+/CD4− cells, never
expressed NTPDase2. It is widely accepted that the neurological
impairments in EAE are induced by pathogenic CD4+ infiltrates,
which abundantly express NTPDase1/CD39 and eN/CD73
(Hernandez-Mir and McGeachy, 2017). Given the significant
number of CD4+NTPDase2+ T cells in DLN, it is of note
that these cells were never observed within CNS infiltrates. The
finding also suggests that CD4+ NTPDase2+ cells do not enter
the CNS parenchyma during EAE and do not contribute to the
initiation of EAE.
Beyond these conclusions, a literature survey on regulatory
elements and acting transcription factors in the promoter region
of a gene encoding NTPDase2 led us to several interesting
implications. The promoter region of rat Entpd2 comprises
two IL-6 responsive elements (IL-6 RE; Yu et al., 2008). The
interleukin (IL)-6, which functions as Th17 and B cells growth
and differentiation factor (Serada et al., 2008), attracts increasing
attention in recent years as an important cytokine involved in
inflammatory diseases of the CNS, including MS/EAE (Fujimoto
et al., 2008; Janssens et al., 2015). Since markedly elevated IL-6
levels are detected in CSF and plasma of MS patients, and since
the cytokine acts as a suppressor of Entpd2 (Yu et al., 2008), it is
most likely that the down-regulation of NTPDase2 during EAE
is induced by IL-6-mediated suppression of Entpd2. Promoter
regions of human ENTPD2 and mouse Entpd2 contain yet
another important immune-related regulatory binding site,
GATA-3 binding site (Chadwick and Frischauf, 1997). GATA-3
is a zink-finger transcription factor that directs CD4+ cell
polarization towards Th2 subtype, by inducing expression of
Th2-type cytokines (Zhu et al., 2004; Evans and Jenner, 2013)
and by inhibiting expression of Th1-type master cytokine,
interferon-γ (Lee et al., 2000). Therefore, since ENTPD2
is one of the GATA-3 linked genes (Dydensborg et al.,
2009), it may be speculated that its expression on T cells
characterizes the fully developed Th2 cell phenotype. Since
Th1 plays role in induction, while Th2 response prevails in
the recovery phase of EAE (Nagelkerken, 1998), a second
implication that may emerge from our data is that the reduction
of CD4+/NTPDase2+ cell number during Eo may reflect
prevalence of Th1, while increase in CD4+/NTPDase2+ cell
numbermay reflect a shift to Th2 response during recovery phase
of EAE.
To summarize, the main goal of our study was to complement
the existing knowledge on the involvement of purinergic
signaling in the sequence of events leading to EAE, by describing
alterations in NTPDase2 and ADP-sensitive P2 receptors
expression. Our results demonstrate that the onset of EAE is
associated with downregulation of gene and protein expression
of NTPDase2, P2Y1 and P2Y12 receptors, while the recovery from
EAE is associated with the baseline gene and protein expression
of NTPDase2 and P2Y1 receptor and strong upregulation of
P2Y12 and P2Y13 receptors in the spinal cord of the affected
animals. The findings suggest a possible link between ADP
signaling and the pathophysiological processes in EAE. Further
studies are needed to unveil the signals that initiate the
observed alterations in NTPDase2 expression and embed them
in the neuroinflammatory cascade which results in EAE and
neuroimmune diseases in general.
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FIGURE S1 | Western blot calibration curve. (A) Twofold serial dilutions of
sample proteins were resolved on SDS-PAGE, electrotransferred to
Immobilon-P transfer membrane and incubated with rabbit polyclonal primary
anti-NTPDase2 antibodies (1:1000 dilution in TBST) and HRP-conjugated
secondary antibodies, using ECL substrate. After 1-min film exposure, the
support membrane was scanned and the digital image was analyzed using
ImageJ. A calibration curve is constructed by plotting the optical density readings
against different amounts of sample proteins to construct. The signal was linear
accross the range of 9-20µg of sample proteins. Asterisk denote the sample
amount used for quantification of NTPDase2 protein abundance on Western
blot. (B) Representative support membrane showing serial dilutions of sample
proteins probed with the antibodies directed against to NTPDase2 and β-actin.
FIGURE S2 | Merged and single-channel immunofluorescence images related
to Figures 5A–H. Cross-sections of the lumbosacral part of the spinal cord
are stained for NTPDase2 (red) and GFAP (green) and nuclei are
counterstained with Hoechst (blue). The scale bar = 20 µm.
FIGURE S3 | Merged and single-channel immunofluorescence images related
to Figures 5I–P. Cross-sections of the lumbosacral part of the spinal cord are
stained for NTPDase2 (red fluorescence) and nestin (green fluorescence) and
nuclei are counterstained with Hoechst (blue fluorescence). The scale
bar = 20 µm.
FIGURE S4 | Merged and single-channel immunofluorescence images related
to Figures 6I–P. Cross-sections of the lumbosacral part of the spinal cord are
stained for NTPDase2 (red fluorescence) and CD68 (green fluorescence) and
nuclei are counterstained with Hoechst (blue fluorescence). The scale
bar = 20 µm.
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